Search - tctmd.com

Displaying 21 - 40 of 108

Sort: Relevancy | Date

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

L.A. McKeown

March 09, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Conference News TCT 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

Todd Neale

September 22, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

Presentation

Mortality Following Nonemergent, Uncomplicated TLR After PCI

April 20, 2018

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Three

Shelley Wood

November 01, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

Advertisement

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Mortality Following Nonemergent, Uncomplicated TLR After PCI

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Live From Denver: TCT 2017, Day Three

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content